Plasma pharmacokinetics, bioavailability and tissue distribution of agnuside following peroral and intravenous administration in mice using liquid chromatography tandem mass spectrometry

Show simple item record

dc.contributor.author Ramakrishna, Rachumallu
dc.contributor.author Bhateria, Manisha
dc.contributor.author Singh, Rajbir
dc.contributor.author Puttrevu, S K
dc.contributor.author Bhatta, R S
dc.date.accessioned 2017-04-24T09:30:30Z
dc.date.available 2017-04-24T09:30:30Z
dc.date.issued 2016
dc.identifier.citation Journal of Pharmaceutical and Biomedical Analysis, 2016, 5,(125),154-64 en
dc.identifier.uri http://hdl.handle.net/123456789/1679
dc.description.abstract Agnuside (AGN), an iridoid glycoside, is the chemotaxonomic marker of the genus Vitex which has gained enormous attention by virtue of its potential health benefits. Regardless of claiming many therapeutic applications reports demonstrating its pharmacokinetics or quantification in biomatrices are lacking. This is the first report which presents a sensitive liquid chromatography coupled to a tandem mass spectrometry (LC-MS/MS) method for the quantification of AGN in mice plasma and various tissues (including liver, intestine, spleen, kidney, heart, lungs and brain). AGN was extracted from the biological samples using protein precipitation followed by liquid-liquid extraction and the separation was achieved on C18 reversed phase column with a mobile phase consisted of 0.1% formic acid in acetonitrile - 0.1% formic acid in triple distilled water (92:8, v/v) at a flow rate of 0.7 mL/min. The MS/MS detection was performed by electrospray ionization (ESI) using multiple reaction monitoring (MRM) in negative scan mode. The bioanalytical method was found linear over the concentration range of 1-4000 ng/mL for plasma and tissue homogenates (r2≥ 0.990). The lower limit of quantitation (LLOQ) for all matrices was 1 ng/mL. Intra-day and inter-day variance and accuracy ranged from 90-110% and 1-10%, respectively. Matrix effect and recoveries were well within the satisfactory limits. The validated method was applied successfully to measure AGN concentrations in plasma and tissues following intravenous (i.v.) and peroral (p.o.) administration to mice. Maximal AGN concentrations in plasma and tissues were reached within 30-45 min. The mean absolute bioavailability (%F) of AGN was ~ 0.7%. After oral administration, AGN was most abundant in intestine, followed by kidney, liver, spleen, brain, lungs and heart. The identified target tissues of AGN may help in understanding its pharmacological action in vivo. en
dc.format.extent 927826 bytes
dc.format.mimetype application/pdf
dc.language.iso en en
dc.relation.ispartofseries CSIR-CDRI Communication No. for this manuscript is 9198. en
dc.subject Agnuside en
dc.subject Chaste tree berry en
dc.subject LC-MS/MS en
dc.subject Pharmacokinetics en
dc.subject Bioavailability en
dc.subject Tissue distribution en
dc.title Plasma pharmacokinetics, bioavailability and tissue distribution of agnuside following peroral and intravenous administration in mice using liquid chromatography tandem mass spectrometry en
dc.type Article en


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account